Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expression of Exosomal Markers (CD63 and CD9) in Lesional Skin of Vitiligo Patients Before and After Narrow-Band Ultraviolet B Therapy: An Immunohistochemical Study

NCT07796893 is registered in ClinicalTrials.gov with Amany El-Agamy Ibrahim El-Samadony as lead sponsor.

NCT NCT07796893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07796893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expression of Exosomal Markers (CD63 and CD9) in Lesional Skin of Vitiligo Patients Before and After Narrow-Band Ultraviolet B Therapy: An Immunohistochemical Study
Lead sponsor
Amany El-Agamy Ibrahim El-Samadony
Phase
Not applicable
Overall status
Completed
Start date
May 20, 2024
Completion date
January 1, 2026
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vitiligo